Altargo

GSK has launched a new topical antibiotic for the short-term treatment of impetigo, infected small lacerations, abrasions or sutured wounds, in adults and children from nine months of age.

PHARMACOLOGY

Retapamulin is the first in a new class of topical antibiotics called pleuromutilins. Pleuromutilins selectively inhibit bacterial protein synthesis at a unique site on the 50S subunit of the bacterial ribosome that is distinct from the binding sites of other non-pleuromutilin antibacterial agents that interact with the ribosome.

Due to its distinct mechanism of action, retapamulin does not demonstrate target-specific cross-resistance with other classes of antibacterial agents.

Retapamulin is predominantly bacteriostatic against S. aureus and S. pyogenes

CLINICAL STUDIES

In a phase III study, retapamulin was shown to be superior to placebo in adults and children with impetigo. The clinical success rate was 85.6 per cent versus 52.1 per cent for retapamulin and placebo, respectively.1

In other studies, retapamulin demonstrated noninferiority to two other antibacterial treatments. Retapamulin ointment 1% (twice daily for five days) showed comparable efficacy with sodium fusidate ointment 2% (three times daily for seven days) in adults and children (>9 months) with impetigo (n=519).2

In addition, retapamulin was as effective as oral cefalexin 500mg twice daily for 10 days in the treatment of secondarily infected dermatitis in patients aged nine months and older (n=546). 3

REFERENCES
1. GSK Clinical Trial Register. Date accessed: 14.02.08.
2. Oranje A, Chosidow O, Sacchindanand S et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology 2007;215: 331–40.
3. Parish L, Jorizzo J, Breton J et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized
controlled trial. J Am Acad Dermatol 2006;55(6): 1003–13

View Altargo drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases